Why this matters now
The U.S. Treasury Department and IRS said they will issue guidance to resolve the key federal tax questions created by the Justice Department’s new Final Order on medical marijuana. The agencies signaled that the DOJ action will carry “significant positive tax consequences” for affected businesses and previewed topics the guidance will cover, including how Internal Revenue Code Section 280E applies after rescheduling and a transition rule for when changes take effect.
DOJ’s order moves marijuana in FDA‑approved products and marijuana covered by a state medical marijuana license into Schedule III under the Controlled Substances Act, while leaving unlicensed bulk marijuana and adult‑use programs unchanged. Media and advocacy groups add that DEA plans to hold a new administrative hearing on June 29, 2026 to consider broader rescheduling beyond medical programs.
What Treasury’s move could change
For “plant‑touching” medical cannabis operators, rescheduling generally removes the 280E prohibition on deducting ordinary and necessary expenses, lowering effective tax rates going forward. Treasury also previewed guidance on apportionment for businesses with multiple activities (for example, a company involved in both medical cannabis and other operations) and a transition rule pegging changes to the taxable year that includes the Final Order’s effective date. That preview gives finance teams a roadmap for modeling cash taxes, deferred tax assets, and covenant impacts ahead of filing season.
For carriers, the tax headline primarily affects customers. However, some fleets operate licensed, intrastate cannabis transport subsidiaries. Those entities may see margin lift as their medical‑market shippers regain deductibility and improve payment terms—potentially easing the cash‑only constraints that have complicated collections and insurance underwriting. Newsroom reporting underscores that the immediate policy shift is limited to medical programs; adult‑use remains outside the order.
Operational impacts for owner‑operators and fleets
- Demand outlook: Expect steadier intrastate medical volumes and opportunities in secure and temperature‑controlled final‑mile. That said, interstate cannabis transport remains constrained; the order does not legalize adult‑use or unlicensed bulk product, and DEA registration and state rules still govern who can handle Schedule III substances.
- Cash flow and credit: As 280E pressure eases for medical operators, shippers may improve days‑payable cycles and move away from cash, which can reduce carrier security risks around collections and cash handling. Treasury’s framing of “significant positive tax consequences” supports this thesis.
- Contracts and pricing: Consider re‑benchmarking rates and surcharges tied to cash‑handling, security, and insurance as medical shippers’ cost of capital and tax drag decline. Build short “reopener” clauses tied to forthcoming IRS guidance to adjust as rules are finalized.
Safety and compliance: nothing changes (yet) for CDL drug testing
DOT’s Office of Drug & Alcohol Policy and Compliance has stated that, until federal rescheduling is complete and DOT regulations are updated, marijuana remains prohibited for safety‑sensitive employees, including CDL drivers. As of today, DOT’s most recent notice keeps the testing panel and MRO verification rules in place. Carriers should maintain zero‑THC policies, Clearinghouse reporting, and supervisor training under 49 CFR Part 40.
What to watch next
- IRS guidance drop: Treasury previewed a transition rule tied to the Final Order’s effective date and apportionment for mixed‑activity businesses. Until that guidance lands, tax advisors are likely to recommend caution on amended returns and method changes.
- DEA’s June hearing: Broader rescheduling could reshape market structure, licensing, and—eventually—logistics rules. Watch for whether adult‑use products move, and any new federal registration pathways affecting transport.
- DOT follow‑through: Monitor ODAPC and FMCSA for any rulemaking that could reconcile drug‑testing policy with Schedule III status for certain products. Until then, enforcement remains status quo.
Bottom line for trucking: Treasury’s announcement is a tax turning point for medical‑market shippers, not a greenlight for interstate cannabis freight or a change in CDL testing. Position your fleet to capture compliant medical‑program haulage, tighten contracts around evolving rules, and stay close to your tax counsel as IRS guidance arrives.
Sources Consulted: U.S. Department of the Treasury; Oregon Public Broadcasting (NPR); U.S. Department of Transportation ODAPC; NORML.
Need to file your Form 2290?
Join thousands of owner-operators and carriers who trust HeavyTax.com for fast and easy HVUT e-filing.
This article was prepared exclusively for truckstopinsider.com. For professional tax advice, consult a qualified professional.
